Related Experiment Video
Updated: Jul 13, 2026

Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation
Published on: June 21, 2016
RXR is an essential component of the oncogenic PML/RARA complex in vivo
Jun Zhu1, Rihab Nasr, Laurent Pérès
1CNRS/University Paris VII UMR 7151, laboratoire associé N11 de la Ligue contre le Cancer, Hôpital St. Louis, 1, avenue Claude Vellefaux, 75475 Paris Cedex 10, France.
Abstract:
Although PML-enforced RARA homodimerization allows PML/RARA to bind DNA independently of its coreceptor RXR, the latter was identified within the PML/RARA complex. We demonstrate that a PML/RARA mutant defective for RXR binding fails to trigger APL development in transgenic mice, although it still transforms primary hematopoietic progenitors ex vivo. RXR enhances PML/RARA binding to DNA and is required for rexinoid-induced APL differentiation. In RA-treated PML/RARA-transformed cells, the absence of RXR binding results in monocytic, rather than granulocytic, differentiation. PML/RARA enhances posttranslational modifications of RXRA, including its sumoylation, suggesting that PML-bound sumoylation enzymes target RXRA and possibly other PML/RARA-bound chromatin proteins, further contributing to deregulated transcription. Thus, unexpectedly, RXR contributes to several critical aspects of in vivo transformation.
Insights
Retinoic acid receptor (RXR) is unexpectedly crucial for PML/RARA
Area of Science:
- Molecular Biology
- Hematopoiesis
- Cancer Biology
Background:
- The PML/RARA oncoprotein drives acute promyelocytic leukemia (APL).
- PML/RARA's interaction with coreceptors like RXR is critical for its function.
- RXR's precise role in PML/RARA-mediated leukemogenesis remains incompletely understood.
Purpose of the Study:
- To investigate the essential role of RXR in PML/RARA-induced APL development in vivo.
- To elucidate how RXR influences PML/RARA's DNA binding and transcriptional activity.
- To determine RXR's impact on differentiation therapy for APL.
Main Methods:
- Generation of transgenic mouse models expressing wild-type or RXR-binding-defective PML/RARA.
- Ex vivo transformation of primary hematopoietic progenitors.
- Analysis of APL development, differentiation, and gene expression.
- Assessment of PML/RARA and RXR posttranslational modifications.
Main Results:
- PML/RARA mutants lacking RXR binding fail to induce APL in mice but transform cells ex vivo.
- RXR enhances PML/RARA's DNA binding and is essential for rexinoid-induced differentiation.
- Absence of RXR leads to monocytic differentiation instead of granulocytic differentiation in treated cells.
- PML/RARA promotes RXR sumoylation, suggesting a role in deregulated transcription.
Conclusions:
- RXR is unexpectedly required for PML/RARA's in vivo leukemogenic activity.
- RXR plays a critical role in PML/RARA-driven APL pathogenesis and differentiation.
- Targeting RXR interactions may offer novel therapeutic strategies for APL.
More Related Videos
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
The Ras Gene
Ras is a superfamily...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation

